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ALLOPURINOL-INDUCED SEVERE HYPERSENSITIVITY
WITH ACUTE RENAL FAILURE
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Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital,
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A 62-year-old male was sent to the emergency room due to a high fever and generalized skin rash after
taking allopurinol for 9 days. Physical examination was normal except for the generalized skin rash
presenting with erythematous macules. Complete blood count showed leukocytosis with eosinophilia.
Blood biochemistry showed impaired renal and hepatic function. Pathologic examination concluded that
the skin rash was erythema multiforme. These findings met the diagnostic criteria for allopurinol-induced
hypersensitivity syndrome (AHS). Our patient not only had the most common skin lesion but soon
developed acute renal failure that required intermittent hemodialysis, despite rapid discontinuation of
allopurinol and adequate hydration and steroid therapy. No other causes of acute renal failure were found.
Renal impairment was the worst part of the patient’s condition and he never completely recovered. AHS
should be considered in the differential diagnosis of acute renal and hepatic failure in patients with evidence
of allergy and recent use of allopurinol.
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Allopurinol, a purine inhibitor of the enzyme xanthine
oxidase, inhibits the synthesis of uric acid and has become
the most popular drug for hyperuricemia. It provides
permanent symptom resolution in most patients with gout;
53% of patients receiving allopurinol 300 mg daily achieve
optimal plasma urate concentrations [1]. In some patients,
however, it is poorly tolerated and leads to a severe hy-
persensitivity reaction. We report a case of allopurinol-
induced hypersensitivity syndrome (AHS) with acute renal
failure that required intermittent hemodialysis, despite
rapid discontinuation of allopurinol, adequate hydration,
and steroid prescription. Impaired renal function was
irreversible.
CASE PRESENTATION
A 62-year-old man presented to our emergency room
(ER) with a 4-day history of fever and widespread skin
rash. He had taken allopurinol, 600 mg/day, for asymp-
tomatic hyperuricemia for 9 days. Serum biochemistry re-
vealed a blood urea nitrogen (BUN) of 7.14 mmol/L, se-
rum creatinine of 132.6 µmol/L, aspartate aminotransferase
(AST) of 86 U/L, alanine aminotransferase (ALT) of 180
U/L, and white blood cell count of 8.66 × 109/L. Physical
examination was normal except for a generalized skin rash.
He was given antihistamine and steroid under the im-
pression of urticaria due to allopurinol-induced hyper-
sensitivity. He left the ER with the advice to discontinue
allopurinol and attend follow-up at the gastroenterology
outpatient department (OPD) due to impaired liver function.
No evidence of hepatitis B or C virus infection was found in
the OPD, only fatty liver on sonographic examination. Due
to the worsening rash and intermittent fever, he returned
to the ER the next day. On physical examination, he was
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moderately ill. His temperature was 39.3°C, blood pressure
was 123/81 mmHg, and pulse rate was 87 bpm. The skin
lesions had spread over the whole body surface as ery-
thematous macules and his face was swollen and ery-
thematous. Physical examination of the neck, heart, and
lungs was normal. The liver was palpable 1 cm below the
costal margin and the spleen was impalpable. Examination
of the genitalia and rectum was normal. No edema was
found on the extremities. Serum biochemistry showed
leukocytosis (14.9 × 109/L) with eosinophilia (8.9%). Serum
creatinine was elevated (159.1 µmol/L) and liver enzymes
were also abnormal (AST, 41 U/L; ALT, 112 U/L). There
was mild proteinuria (100 mg/dL), pyuria (white blood cell
count, 5–10/high-powered field), and leukocyte cast
(0–2/low-powered field). Chest radiography showed no
abnormality. The patient was admitted to the infectious
division under the initial impression of urinary tract in-
fection. A first-generation cephalosporin and hydration
therapy were prescribed soon after admission. Urine culture
grew Enterococcus. Renal sonography revealed normal renal
parenchyma without hydronephrosis. Since the skin lesions
progressed from being wheals to erythematous macules,
skin biopsy was performed and showed moderate superficial
perivascular and periadnexal lymphocytic and eosinophilic
infiltration. All of these findings were compatible with
erythema multiforme. Combining this skin diagnosis with
the clinical findings of fever, leukocytosis with eosinophilia,
impaired liver and renal function, and the recent use of
allopurinol, the diagnosis of AHS was made. He was then
given steroid intravenously to relieve the hypersensitivity.
Liver enzyme levels declined gradually. However, despite
hydration and steroid treatment soon after admission, renal
function impairment progressed with severe azotemia and
even anuria. The patient then started intermittent
hemodialysis therapy and was transferred to nephrology
care. His urine output increased to 1,520 mL/day after the
fifth hemodialysis but azotemia persisted. A second renal
sonography revealed normal renal size with evidence of
parenchymal injury. Renal function improved partially after
eight intermittent hemodialysis treatments. He was
discharged 25 days after admission and was followed
regularly at our OPD but had remaining impaired renal
function. His BUN level was 25.71 mmol/L and his creati-
nine level was 415.5 µmol/L 2 months after discharge.
The patient has been followed at our OPD for 3 years
since his AHS episode and renal sonography has recently
shown chronic renal parenchymal disease. The clinical
course is summarized in the Figure; it included skin rash,
fever, signs of oliguria, and initial deterioration and then
partial recovery of renal function accompanying ster-
oid therapy and intermittent hemodialysis during ad-
mission. It is noteworthy that he received steroids from
our OPD. The serial changes in kidney and liver func-
tion and white blood cell and eosinophil counts are sum-
marized in Table 1.
DISCUSSION
Allopurinol is generally considered to be a safe and well-
tolerated drug in treating hyperuricemia [2]; 53% of patients
receiving allopurinol 300 mg daily achieve optimal plasma
urate concentrations [1]. Nevertheless, there are variable
adverse reactions, from itching, skin rash, low-grade fever,
leukocytosis with eosinophilia, and bowel upset to severe
life-threatening adverse effects of acute renal damage and
Figure. Clinical course and changes
in serum creatinine (Cr) levels.
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acute hepatocellular injury, termed AHS [3]. The frequency
of AHS is about one in 260 (0.38%) patients receiving
allopurinol therapy, and it begins within days or weeks of
administration [3]. The acute renal failure in patients with
AHS is usually reversible [1]. However, we report a patient
with irreversible changes in renal function.
The development of AHS is related to the serum level of
oxypurinol, the therapeutic metabolite of allopurinol.
Oxypurinol inhibits xanthine oxidase by binding to it and
preventing the conversion of hypoxanthine and xanthine to
uric acid. Since the clearance of oxypurinol is dependent on
renal excretion, AHS occurs mainly in patients with impaired
renal function. The exact mechanism by which AHS develops
is not clear. It is assumed that accumulation of oxypurinol
triggers a type III hypersensitivity reaction, with develop-
ment of diffuse vasculitis and even Guillain-Barre syndrome,
due to damage of peripheral nerve myelin [4]. Previous
studies also found the deposition of immunoglobulin (Ig)
M at the dermal–epidermal junction and linear deposits of
both γ-globulin and complement along the glomerular
basement membrane [3,5]. Microscopic findings in the
kidney are variable: acute interstitial nephritis [6], focal
segmental glomerulosclerosis [7], and diffuse vasculitis [8]
have all been described.
More than 80% of reported cases of allopurinol hyper-
sensitivity had evidence of renal functional impairment be-
fore treatment, and most patients took the standard dose
of 300 mg daily without any modification. Normally, the dose
of allopurinol given to patients should be based on creatinine
clearance (Table 2) [5]. In this patient, the dose of 600 mg/day
was apparently too high for his age and too high for such
an asymptomatic patient. AHS could have been avoided with
diet control and a lower dose of allopurinol based on creatinine
clearance if hyperuricemia had persisted.
The presence of a generalized skin rash presenting with
erythematous macules, determined by skin biopsy to be
erythema multiforme, accompanied by other signs such as
fever, leukocytosis with eosinophilia, impaired renal and
liver function, and a history of exposure to allopurinol in
this case met the criteria for AHS [3]. Management of AHS
depends on early recognition of the problem and withdraw-
al of allopurinol as soon as possible. Without early inter-
vention, progressive renal failure is often inevitable and
dialysis therapy is needed. There was an apparent delay in
the diagnosis of AHS in this patient, as he was initially
admitted to the infectious division under the impression of
a urinary tract infection and was then transferred to the
nephrology department due to progressive renal function
deterioration. Delay in referral is often due to the fact that
patients usually present with symptoms and signs mim-
icking urinary tract infection, such as hematuria, pyuria, as
well as leukocyte cast. These findings, however, reflect the
interstitial nephritis induced by the drug [9]. Various drugs
simulate AHS, which is then termed drug hypersensitivity
syndrome (DHS) (Table 3) [10]. DHS should be differen-
tiated from protracted viral infection, hyper-eosinophilic
syndrome, auto-immune disease, and lymphoma [10]. This
Table 2. Maintenance dose of allopurinol based on
individual creatinine clearance rates (Ccr)
Ccr (mL/min) Allopurinol
0 100 mg/3 days
10 100 mg/2 days
20 100 mg/day
40 150 mg/day
60 200 mg/day
80 250 mg/day
100 300 mg/day
Table 1. Serial changes in kidney and liver function and white blood cell (WBC) and eosinophil counts
Component (normal range) D–1 (O) D1 (ER) D2 D3 D4 D7 D12 D25
BUN, mmol/L (2.5–6.4) 7.1 7.9 10.0 20.7 29.6 41.4 58.0 42.5
Cr, µmol/L (53–115) 133 159 201 398 593 1,000 1,291 991
AST, U/L (10–42) 86 41 28 23
ALT, U/L (10–40) 180 112 74 55
WBC count, × 109/L (4.0–10.0) 8.66 14.99 10.98 9.24 8.39 6.97
Eosinophil count, % (0–4) 8.9 2.4 2.4
D–1 = 1 day before admission; DX = X days after admission; O = 1st visit to outpatient department; ER = 2nd visit to emergency room;
BUN = blood urea nitrogen; Cr = serum creatinine; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
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patient was initially diagnosed as having ordinary urinary
tract infection because the life-threatening events of kidney
and liver failure were ignored. The increases in serum
creatinine concentration from 132.6 to 159.1 µmol/L in less
than 2 days in this patient should have alerted doctors to the
rapid progression of renal damage.
In addition to the cessation of allopurinol in suspected
cases of AHS, supportive and steroid therapies are also
important. The length of steroid treatment should be
adequate, since the early tapering of steroid may induce
relapse of AHS and permanently impaired renal function
[3]. In our case, the steroid was given early, the second day
after admission, until after the hospitalization period was
over. In spite of this management, irreversible renal damage
occurred and the patient’s kidneys progressively shrank. In
patients for whom allopurinol is absolutely necessary,
desensitization could be considered in those who have
experienced a mild hypersensitivity reaction [11].
Alternatively, benzbromarone has been suggested as an
effective serum uric acid-lowering drug in patients with
both hyperuricemia and renal insufficiency [1,12].
Some patients have no reaction after higher-dose allo-
purinol treatment of hyperuricemia. The low prevalence of
AHS in these patients cannot be adequately explained. A
recent study of Han Chinese showed a strong association of
a genetic marker, the human leukocyte antigen HLA-B*1502,
with Stevens-Johnson syndrome induced by carbamazepine,
a drug commonly prescribed for managing seizures [13].
Whether there is also any association with a genetic marker
in AHS requires further investigation.
In summary, we report the development of a severe
Table 3. Drugs inducing hypersensitivity syndrome
Aromatic antiepileptics Phenytoin
Phenobarbital
Carbamazepine
Dapsone
Allopurinol
Minocycline
Antiretroviral drugs Nevirapine
Abacavir
hypersensitivity reaction with acute renal failure in a patient
with impaired renal function who took a high dose of
allopurinol to treat asymptomatic hyperuricemia. Since
renal function was not completely restored in this patient,
we would emphasize that the adverse reactions of allo-
purinol should be kept in mind and that dose modification
is needed in patients with pre-existing impaired renal
function.
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